All In Biotech

Drug Trial Radar · NCT02281682

IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis

Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study

Last checked: Nov 20, 2026Latest source record: Oct 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 624 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

624

Actual

Start

Nov 2014

Primary completion

Jul 2018

Study completion Dec 2018

Sponsor

Lead sponsor
Maastricht University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-centre randomised controled single blind clinical phase IV trial with the aim to determine the most effective treatment in terms of lesion reduction, costs and patient satisfaction in treatment of actinic keratosis (AK), when comparing topical treatment with photodynamic therapy (PDT), 5% 5-fluorouracil (5-FU) cream, 5% Imiquimod (IMI) cream and ingenol mebutate (IM) gel.

Conditions

  • Keratosis, Actinic

Interventions

  • ImiquimodDrug

    three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage

  • 5-fluorouracilDrug

    during 4 (consecutive) weeks twice daily. Prior to treatment: curettage

  • Ingenol mebutateDrug

    during 3 (consecutive) days once daily. Prior to treatment: curettage

  • methylaminolevulinate photodynamic therapyProcedure

    methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. treatment succesTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Maastricht UMC

    Maastricht, Limburg, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.